Haematopoietic stem cell transplantation (HSCT) is central to the management of many
haematological disorders. A frequent complication of HSCT is acute graft-versus-host …

C lostridium difficile is the leading cause of infectious nosocomial diarrhoea in developed
countries, with a measured incidence of approximately five episodes per 10 000 days of …

Fecal microbiota transplant (FMT) is recommended for Clostridium difficile infection (CDI)
treatment; however, use in solid organ transplantation (SOT) patients has theoretical safety …

Background More than 95% of human diseases may be related to the disturbance of gut
microbes. As a treatment method that extensively regulates the gut microbes, fecal …

Background Clostridium difficile (C. difficile) is the pathogen that most commonly causes
nosocomial and antibiotic-associated diarrheal disease. Optimized algorithms for diagnosis …

Fecal microbiota transplantation (FMT) has been shown to be safe and efficacious in
individuals with refractory Clostridium difficile. It has not been widely studied in individuals …

Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to
prevent and manage. Despite intense national and international attention the incidence of …

Clostridium difficile infection (CDI) is an emerging problem worldwide associated with
significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed …

Increasing antibiotic resistance in bacteria causing endogenous infections has entailed a
need for innovative approaches to therapy and prophylaxis of these infections and raised a …

Clostridium difficile is a gram-positive anaerobic bacillus responsible for approximately 1 of
5 cases of antibiotic-associated diarrhea. C difficile infection (CDI) is defined by at least 3 …